Mycobacterium haemophilum: Difference between revisions
Jump to navigation
Jump to search
Shanshan Cen (talk | contribs) |
Shanshan Cen (talk | contribs) |
||
| Line 45: | Line 45: | ||
==Treatment== | ==Treatment== | ||
===Antimicrobial regimen=== | ===Antimicrobial regimen=== | ||
* | *1. '''In vitro''' <ref>{{Cite journal| doi = 10.1164/rccm.200604-571ST| issn = 1073-449X| volume = 175| issue = 4| pages = 367–416| last1 = Griffith| first1 = David E.| last2 = Aksamit| first2 = Timothy| last3 = Brown-Elliott| first3 = Barbara A.| last4 = Catanzaro| first4 = Antonino| last5 = Daley| first5 = Charles| last6 = Gordin| first6 = Fred| last7 = Holland| first7 = Steven M.| last8 = Horsburgh| first8 = Robert| last9 = Huitt| first9 = Gwen| last10 = Iademarco| first10 = Michael F.| last11 = Iseman| first11 = Michael| last12 = Olivier| first12 = Kenneth| last13 = Ruoss| first13 = Stephen| last14 = von Reyn| first14 = C. Fordham| last15 = Wallace| first15 = Richard J.| last16 = Winthrop| first16 = Kevin| last17 = ATS Mycobacterial Diseases Subcommittee| last18 = American Thoracic Society| last19 = Infectious Disease Society of America| title = An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases| journal = American Journal of Respiratory and Critical Care Medicine| date = 2007-02-15| pmid = 17277290}}</ref> | ||
:* Susceptible: [[Amikacin]], [[Clarithromycin]], [[Ciprofloxacin]], [[Rifampin]], and [[Rifabutin]] | :* Susceptible: [[Amikacin]], [[Clarithromycin]], [[Ciprofloxacin]], [[Rifampin]], and [[Rifabutin]] | ||
:* Less susceptible: [[Doxycycline]] and [[Sulfonamides]] | :* Less susceptible: [[Doxycycline]] and [[Sulfonamides]] | ||
* Disseminated disease | *2. '''Disseminated disease''' | ||
:* Preferred regimen: [[Clarithromycin]] {{and}} [[Rifampin]] {{and}} [[Rifabutin]] {{and}} [[Ciprofloxacin]] | :* Preferred regimen: [[Clarithromycin]] {{and}} [[Rifampin]] {{and}} [[Rifabutin]] {{and}} [[Ciprofloxacin]] | ||
Revision as of 14:27, 15 July 2015
| Mycobacterium haemophilum | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scientific classification | ||||||||||||||
| ||||||||||||||
| Binomial name | ||||||||||||||
| Mycobacterium haemophilum Sompolinsky et al. 1978, ATCC 29548 |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Mycobacterium haemophilum
Description
Short, occasionally curved, gram-positive, nonmotile and strongly acid-fast rods.
Colony characteristics
- Nonpigmented and rough to smooth colonies.
Physiology
- Media have to be supplemented with 0.4% haemoglobin or 60µM hemin (factor X) or 15mg/ml ferric ammonium citrate respectively, but not with FeCl3 or catalase.
- Slow growth on Löwenstein-Jensen media or Middlebrook 7H10 agar at 32°C within 2-4 weeks.
- Growth slower at 25°C and 35°C and absent at 37°C.
- Strictly intracellular growth in tissue cultures of fibroblasts.
Differential characteristics
- Unique among mycobacteria in its requirement for hemin or ferric ammonium citrate for growth.
Distribution.
Pathogenesis
- Infects patients with suppressed immune systems.
- Clinical presentation: multiple skin nodules occurring in clusters or without definitive pattern, commonly involving the extremities. Abscesses, draining fistulas and osteomyelitis may be associated with the nodules. Paediatric patients with localised cervical lymphadenopathy.
- Biosafety level 2
Type Strain
First isolated in Israel from a subcutaneous granuloma from a patient with Hodgkin's disease. An environmental reservoir is presumed. Strain ATCC 29548 = CCUG 47452 = CIP 105049 = DSM 44634 = NCTC 11185.
Treatment
Antimicrobial regimen
- 1. In vitro [1]
- Susceptible: Amikacin, Clarithromycin, Ciprofloxacin, Rifampin, and Rifabutin
- Less susceptible: Doxycycline and Sulfonamides
- 2. Disseminated disease
- Preferred regimen: Clarithromycin AND Rifampin AND Rifabutin AND Ciprofloxacin
References
- ↑ Griffith, David E.; Aksamit, Timothy; Brown-Elliott, Barbara A.; Catanzaro, Antonino; Daley, Charles; Gordin, Fred; Holland, Steven M.; Horsburgh, Robert; Huitt, Gwen; Iademarco, Michael F.; Iseman, Michael; Olivier, Kenneth; Ruoss, Stephen; von Reyn, C. Fordham; Wallace, Richard J.; Winthrop, Kevin; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America (2007-02-15). "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases". American Journal of Respiratory and Critical Care Medicine. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. ISSN 1073-449X. PMID 17277290.
- Sompolinsky et al. 1978. Mycobacterium haemophilum sp. nov., a new pathogen of humans. International Journal of Systematic Bacteriology, 28, 67-75.